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Background: Viability seems to be important in preventing ventricular remodeling after acute myocardial infarction
(AMI). We investigated the influence of viability, as demonstrated with low-dose dobutamine echocardiography,
and the role of early revascularization on the process of left ventricular (LV) remodeling after AMI.
Methods: We retrospectively investigated 224 patients who were initially included in the viability-guided angioplasty
after acute myocardial infarction-trial (VIAMI-trial). Patients in the VIAMI-trial did not undergo a primary or rescue
percutaneous coronary intervention and were stable in the early in-hospital phase. Patients underwent viability
testing within 72 hours after AMI. Patients with viability were randomized to an invasive strategy or an
ischemia-guided strategy. Follow-up echocardiography was performed at a mean of 205 days. In this echocardiographic
substudy, patients were divided into three new groups: group 1, viable and revascularized before follow-up
echocardiogram; group 2, viable, but medically treated; and group 3, non-viable patients.
Results: Group 1 showed preservation of LV volume indices. The ejection fraction (EF) increased significantly
from 54.0% to 57.5% (P = 0.047). Group 2 showed a significant increase in LV volume indices with no improvement in
EF (53.3% versus 53.0%, P = 0.86). Group 3 showed a significant increase in LV volume indices, with a decrease in EF
from 53.5% to 49.1% (P = 0.043). Multivariate logistic regression analysis indicated the number of viable segments and
revascularization during follow-up as independent predictors for EF improvement, especially in patients with lower EF
at baseline.
Conclusion: Viability early after AMI is associated with improvement in LV function after revascularization. When viable
myocardium is not revascularized, the LV tends to remodel with increased LV volumes, without improvement of EF.
Absence of viability results in ventricular dilatation and deterioration of EF, irrespective of revascularization status.
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Following acute myocardial infarction (AMI) the develop-
ment of left ventricular (LV) dilatation, caused by alter-
ations in architecture and function of the left ventricle, is
one of the most feared consequences of the complex
process of ventricular remodeling. Ventricular remodeling
involves both the infarcted and noninfarcted zone, and is
considered as one of the major determinants of poor out-
come [1]. Gaudron and colleagues showed that predictors
of progressive LV dilatation and chronic LV dysfunction
include ventriculographic LV size, LV ejection fraction
(EF) at day 4 after AMI, infarct location (especially anter-
ior), and Thrombolysis In Myocardial Infarction (TIMI)
flow grade of the infarct-related artery (IRA) [2]; also, per-
sistent occlusion of the IRA has been indicated as a pre-
dictor for ventricular remodeling [3-5]. The relative
contribution of all these factors in the remodeling process
remains unclear, but the patency of the IRA assumes
particular importance because it is a risk factor amen-
able for intervention. Reperfusion therapy has contrib-
uted to an important reduction in mortality after AMI by
limiting myocardial necrosis and therefore preservation of
LV function.
Viability and remodeling
The transmural extent of myocardial necrosis and the
presence or absence of myocardial viability are import-
ant predictors for the onset of ventricular remodeling.
Furthermore, the extent of microvascular obstruction as
detected by cardiovascular magnetic resonance (CMR)
influences the functional recovery after AMI [6].
At rest, most of the LV wall thickening reflects thick-
ening of the inner layer of the myocardium. The middle
layer contributes only moderately to overall wall thick-
ening, while the outer third contributes only minimally
[7]. Although the middle and outer layers of the myocar-
dium thicken little at rest, they thicken more with cat-
echolamine stimulation and thus contribute to overall
wall thickening during dobutamine infusion [8]. Dobuta-
mine responsiveness with wall thickening may therefore
indicate the presence of viable myocardium in the middle
and outer layers of the ventricular wall. An experimental
study by Hochman and Bulkley indicated that only a small
rim of viable epicardial myocardium prevented infarct ex-
pansion [9].
Older necropsy studies have already shown that the
degree of transmurality was an important predictor of
infarct expansion [10]. Later on, this concept of remod-
eling and transmurality was confirmed by CMR studies
[11,12]. Viability in the infarct zone, generally located in
the outer layers of the ventricular wall, prevents remodel-
ing by limiting infarct expansion. However, myocardial
viability may only be temporarily present if no revasculari-
zation takes place. Knudsen and colleagues demonstrateda time-dependent loss of viability during the first 3 months
after AMI [11].
Many studies showed a favorable effect of post-infarction
viability on LV function and volume parameters. These ef-
fects were demonstrated in a population after AMI with
successful percutaneous coronary intervention (PCI) or
treatment with thrombolysis [13-15].
Viability can be detected with several imaging modal-
ities. Low-dose dobutamine echocardiography (LDDE) is
considered to be the test of first choice in patients with
recent AMI, as it is a bedside tool with a diagnostic
accuracy of about 80%, which is comparable to scinti-
graphical techniques (single photon emission computed
tomography/positron emission tomography), and can be
performed easily and safely 24 hours after AMI [16,17].
Nowadays, CMR with late gadolinium enhancement re-
veals better diagnostic accuracy, even in patients with se-
vere LV dysfunction, but lacks the usefulness of a bedside
tool [12,18].
The aim of this study is to investigate the influence of
viability, demonstrated with LDDE, and the role of early




We retrospectively studied patients who were initially
included in the viability-guided angioplasty after acute
myocardial infarction-trial (VIAMI-trial; NCT00149591:
http://www.clinicaltrials.gov). The VIAMI-trial was a pro-
spective, multicenter, randomized controlled clinical trial
[19,20]. Between April 2001 and January 2006, 291 pa-
tients were enrolled from 11 participating Dutch hospitals.
Patients admitted to any of the participating centers
with a (sub)acute myocardial infarction, who were not
treated by primary or rescue angioplasty, and who were
stable during the first 48 hours after the acute event, were
screened for the study. Stable patients revealed no signs of
ongoing ischemia based on electrocardiographic charac-
teristics or persistent chest discomfort.
Patients less than 80 years of age were considered suit-
able for the study when they met the criteria for definite
myocardial infarction: a significant rise in creatine kinase-
MB levels (twice the upper limit of normal), 1 mm ST seg-
ment elevation in two or more standard leads or 2 mm ST
segment elevation in two contiguous chest leads, and/or
the development of Q waves.
Patients underwent LDDE for the detection of viability
within 72 hours after AMI. Patients with viability in the
infarct area were randomized to an invasive or a conser-
vative treatment strategy. The invasive strategy patients
underwent in-hospital coronary angiography with the
intention to perform PCI with stenting of the IRA. In the
conservative group, an ischemia-guided approach was
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a positive test for ischemia, coronary angiography was
strongly recommended.
Patients were followed up for 3 years, with the intension
to perform an echocardiogram after 3, 6, and 12 months.
Eventually, 224 patients had an evaluable baseline and
follow-up echocardiogram.
In this echocardiographic substudy, patients were di-
vided into three new groups to investigate the influence
of revascularization and viability on LV remodeling.
These groups were based on their initial randomization,
LDDE response, and revascularization status. Ninety four
patients were classified as viable and were revascularized
before their follow-up echocardiogram (group 1). Seventy
one patients were also viable, but medically treated with-
out revascularization (group 2). Fifty nine patients were
classified as non-viable (group 3).
Ethical approval and consent
The VIAMI-trial was approved by the Clinical Research
Ethical Committee of the VU University Medical Center
(ref: 1999/123). The local research ethics committee of
each participating hospital approved for local feasibility
(see Additional file 1). All eligible patients provided writ-
ten informed consent. The study complied with the Dec-
laration of Helsinki.
Echocardiographic examination
The baseline, LDDE, and follow-up echocardiograms were
performed with a Hewlett-Packard Sonos 5500 imaging
system (2.5 and 3.5 MHz transducers; Hewlett-Packard
Inc., Andover, MA, USA). All patients were imaged while
taking their prescribed medication. Beta-blockers were
withdrawn 24 hours before the LDDE. At baseline and at
follow-up, a complete cross sectional ultrasound examin-
ation was performed according to the guidelines of the
American Society of Echocardiography under resting con-
ditions [21].
To perform the LDDE, dobutamine was administrated
intravenously at doses of 5, 10, and 15 μg/kg/min, for
5 minutes at each dose. When a 10% increase in heart
rate was not achieved with 15 μg/kg/min, a 5-minute in-
fusion with 20 μg/kg/min could be used as the final
stage of the procedure [22-24]. Patients were continu-
ously monitored by a 12-lead electrocardiogram, and
blood pressure was recorded at the end of each stage.
The criteria for stopping dobutamine infusion were as
follows: hypotension decrease in systolic or diastolic blood
pressure of more than 30 mmHg; hypertension (systolic
blood pressure above 220 mmHg, diastolic pressure
above 130 mmHg); intolerable angina; supraventricular
tachycardia; ventricular tachycardia, significant ST segment
depression or elevation (more than 2 mm); significant is-
chemia on the echocardiogram (more than 1 segment). Allpatients reached the 10% increase in heart rate. Patients
with significant ischemia were excluded from the study be-
cause coronary angiography was mandatory.
All echocardiographic images were sent to the core-lab
(VU University Medical Center) and analyzed by two ex-
perienced observers. A third observer was used in case of
disagreement to reach consensus.
Echocardiographic measurements
Baseline and follow-up
Five standard views were obtained: the parasternal long-
axis and short-axis view (mid-ventricular view) and the
apical two-, three- and four-chamber view. A 16-segment
model was used in which the apex is divided into four seg-
ments. Segmental wall motion and thickening was scored
according to a 4-point scale: 1 = normal, 2 = hypokinetic,
3 = akinetic, and 4 = dyskinetic. Wall motion score index
was calculated by summing the scores for each segment
and dividing by the number of segments analyzed. LV vol-
umes and EF were measured by use of the modified Simp-
son’s rule algorithm from orthogonal apical long-axis
projections (four- and two-chamber view) as recom-
mended by the American Society of Echocardiography
[21]. Tracing of the endocardial borders was performed
on a digitized frame. The mean values of at least three
measurements of the technically best cardiac cycles were
taken from each examination. EF was calculated as:
End diastolic volume–end systolic volume½ =
end diastolic volume  100:
A relative increase of LV ejection fraction >10% at follow-
up was defined as a significant LV improvement [14].
Low-dose dobutamine echocardiogram
Viability was defined as the improvement of wall motion
abnormalities in two or more segments of the infarct
zone. Changes from hypokinesia to normokinesia and
from dyskinesia or akinesia to hypo- or normokinesia are
considered an improvement in wall motion abnormality.
Dyskinesia changing to akinesia was not considered as an
improvement.
Statistical analysis
Baseline descriptive data are presented as mean ± SD.
Differences in clinical and echocardiographic variables
were assessed by unpaired Student’s t test. Differences be-
tween proportions were assessed by chi-square analysis; a
Fisher’s exact test was used when appropriate. The LV
end-diastolic volume (LVEDV) and end-systolic volume
(LVESV) and EF at baseline and at follow-up were com-
pared for mean values and changes over time, using one-
way repeated measures analysis of variance, with time
being the within-subject variable. Variables that were
significantly different between patients with and without
Table 1 Baseline characteristics and echocardiographic data
Viable Non-viable
Revascularized Medical
Characteristic Group 1 (n = 94) Group 2 (n = 71) Group 3 (n = 59) P value*
Male 83% 77% 69% 0.61
Age (years) 61 60 63 0.18
Clinical history
Angina 43% 41% 56% <0.001
Myocardial infarction 7% 3% 12% 0.056
Percutaneous coronary intervention 1% 3% 12% 0.013
Coronary artery bypass graft 0% 0% 0% -
In-hospital
Anterior infarction 29% 31% 46% 0.28
Thrombolysis 56% 49% 47% 0.83
Revascularization 100% 0% 29% <0.001
- Percutaneous coronary intervention 83% 0% 24%
- Coronary artery bypass graft 17% 0% 5%
Peak creatine kinase (U/L) 1,617 ± 1,215 1,804 ± 1,321 1,784 ± 1,654 0.66
Peak creatine kinase-MB (U/L) 165 ± 130 204 ± 182 170 ± 149 0.27
Pathological Q waves (n)† 1.70 ± 1.57 1.96 ± 1.48 2.54 ± 2.00 0.01
Persistent ST elevation >1 mm† 20% 34% 54% <0.001
Echocardiography
Viable segments (16 segments model) (n) 3.39 ± 1.43 3.38 ± 1.27 0.37 ± 0.49 0.95‡
LVEDV (ml) 98.5 ± 33.2 88.4 ± 25.2 89.5 ± 33.7 0.07
LVESV (ml) 47.0 ± 25.1 41.9 ± 19.1 42.9 ± 22.5 0.32
LVEF 54.0% 53.3% 53.5% 0.93
WMI 1.54 ± 0.27 1.57 ± 0.26 1.54 ± 0.30 0.78
Follow-up
Follow-up echocardiogram (days) 226 ± 129 178 ± 127 205 ± 134 0.07
Revascularisation (days) 25 ± 66 NA 48 ± 75 0.16§
Risk factors
Diabetes mellitus 10% 11% 8% 0.63
Hypertension 23% 26% 36% 0.11
Hypercholesterolemia 19% 14% 17% 0.91
Current cigarette smoking 46% 35% 64% 0.003
Family history of coronary artery disease 33% 26% 20% 0.25
Medications at admission
Aspirin 14% 11% 12% 0.76
Beta-blocker 11% 12% 17% 0.58
Statins 17% 5% 10% 0.02
ACE-inhibitor 10% 5% 15% 0.11
Angiotensin II antagonist 4% 6% 7% 0.33
Medications at discharge
Aspirin 95% 99% 88% 0.04
Beta-blocker 97% 93% 92% 0.35
Statins 94% 99% 92% 0.18
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Table 1 Baseline characteristics and echocardiographic data (Continued)
ACE-inhibitor 54% 58% 68% 0.25
Angiotensin II antagonist 3% 7% 8% 0.35
Clopidogrel 65% 11% 22% <0.001
Diuretics 5% 6% 17% 0.02
*Differences between the groups. †On the electrocardiogram at 48 hours after acute myocardial infarction. §Difference between group 1 and 2. Values are shown
as means ± SD unless otherwise indicated. ACE, angiotensin converting enzyme; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction;
LVESV, left ventricular end-systolic volume; NA, not applicable; WMI, wall motion score index.
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mitted for univariate regression analysis. Variables that
showed a significant correlation with LVEF improvement
were included in the multivariate stepwise logistic regres-
sion model to determine the independent correlates. A
probability value of P < 0.05 was considered significant.
All analyses were performed with the use of SPSS soft-
ware, version 16.0 (SPSS, Inc., Chicago, IL, USA).
Results
Of the 224 patients with an evaluable baseline and follow-
up echocardiogram, 83 were randomized to the viable
invasive strategy and 82 to the viable conservative ap-
proach. The remaining 59 patients had no viability and
were followed in the registry group. In the viable invasive
group, 13 patients did not undergo a revascularization
procedure for different reasons (small vessels, multi-vessel
disease without coronary artery bypass graft options, non-
significant stenosis IRA). In the viable conservative group,
24 patients crossed over to the invasive group because of
anginal complaints or proven ischemia before follow-up
echocardiography. For the purpose of this echocardio-
graphic substudy investigating the influence of revasculari-
zation and viability on LV remodeling, we divided the
patients into three new groups: patients with viability and
revascularization before their follow-up echocardiogram
(94 patients, group 1); patients with viability but medically
treated without revascularization before their follow-up
echocardiogram (71 patients, group 2); and patients with-
out viability (59 patients, group 3).
Patient characteristics
Baseline characteristics of the three groups are shown
in Table 1. Most baseline characteristics are similar,Table 2 Baseline and follow-up left ventricular volumes and e
LVEDV (ml) LVESV (ml)
Baseline Follow-up P value Baseline
Group 1 98.5 (33.2) 107.7 (39.3) 0.083 47.0 (25.1)
Group 2 88.4 (25.2) 106.5 (29.9) 0.001 41.9 (19.1)
Group 3 89.5 (33.7) 108.6 (32.9) 0.002 42.9 (22.5)
Values are mean (standard deviation). P values represent differences between base
volume; LVESV, left ventricular end-systolic volume.except for history of angina and PCI, current smoking,
and use of statins. Furthermore, group 3 reveals more
pathological Q-waves and more persistent ST segment
elevation >1 mm on the electrocardiogram 48 hours
after admission. Enzymatic and echocardiographic indi-
cators of infarct size were comparable between the three
groups at baseline.
Left ventricular volumes and ejection fraction
The outcome in the three patient groups is shown in
Table 2 and Figures 1 and 2.
In patients without viability (group 3) a significant in-
crease in LVEDV and LVESV was observed at follow-up,
with a decrease in LVEF from 53.5% to 49.1% (P = 0.043).
Patients with viability who were medically treated during
their follow-up period (group 2) showed a significant in-
crease in LVEDV and LVESV without a change in LVEF
(53.3% versus 53.0%, P = 0.86). In contrast, patients with
viability who were revascularized during follow-up (group
1) showed a non-significant increase in LVEDV, with no
change in LVESV. The LVEF increased significantly from
54.0% to 57.5% (P = 0.047).
In patients without viability (group 3), revascularization
did not lead to improvement in LVEF or volumes. Both
the revascularized (n = 17) and the medically treated (n =
42) patients in the non-viable group showed a significant
increase in LVEDV and LVESV. A non-significant de-
crease in EF is observed in both subgroups (Figure 3 and
Table 3).
Predictors of left ventricular ejection fraction improvement
A significant improvement in LVEF (>10%) occurred in
46% of group 1 versus 31% of group 2 and 19% of group
3 patients (Figure 4). In Table 4 patients were dividedjection fraction
EF (%)
Follow-up P value Baseline Follow-up P value
48.3 (28.9) 0.74 54.0 (12.8) 57.5 (11.5) 0.047
51.7 (23.2) 0.007 53.3 (11.8) 53.0 (9.9) 0.86
57.2 (29.3) 0.004 53.5 (11.3) 49.1 (12.3) 0.043

























Figure 1 Changes in end-systolic volumes. Change in left ventricular end-systolic volume (ESV) between baseline and follow-up in groups 1 to 3.
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The baseline characteristics are comparable. The group
with improvement of LVEF underwent significantly
more revascularization procedures (62 versus 43%, P =
0.008). Furthermore, more viable segments during base-
line LDDE were seen (3.2 versus 2.3, P < 0.001) in this
patient group. Also, the LV volume indices were signifi-

























Figure 2 Changes in ejection fraction. Change in ejection fraction betwe57.7%, P < 0.001). In the univariate analysis, all these
parameters were found to be predictive for LVEF im-
provement. After multivariate logistic regression analysis
was performed, three variables emerged as independent
predictors of LVEF improvement: revascularization pro-
cedure before follow-up echocardiogram, number of












































Figure 3 Changes in ejection fraction in group 3 after revascularization or medical treatment. Change in ejection fraction between
baseline and follow-up in non-viable invasive-treated versus non-viable medically treated group (group 3).
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There was low variability (percentage difference in values)
between LV volume measurements made by two inde-
pendent observers (inter-observer variability). A sample of
25 patients per group was randomly selected and re-
analyzed. Inter-observer variability was 7.25% with a good
intra-class correlation coefficient of 0.86.
The LDDEs were analyzed by two experienced observers.
There was low inter-observer variability in the classifica-
tion of wall motion and the response to low-dose dobuta-
mine (agreement 96%). In only 4% of the LDDE was a
third observer used to reach consensus.Table 3 Baseline and follow-up left ventricular volumes and e
LVEDV (ml) LVE
Baseline Follow-up P value Base
Group 3 (total) 89.5 (33.7) 108.6 (32.9) 0.002 42.9
Group 3 (revascularized) 92.1 (35.1) 117.4 (29.4) 0.030 44.9
Group 3 (medically treated) 88.4 (33.6) 105.0 (33.9) 0.027 42.1
Values are mean (standard deviation). P values represent differences between base
volume; LVESV, left ventricular end-systolic volume.Discussion
Our study shows the importance of revascularization in
patients with viability early after AMI. To the best of
our knowledge this is the largest study investigating the
influence of viability and revascularization on LV remod-
eling in a patient group treated without primary or res-
cue PCI.
Viability and revascularization
Bolognese and colleagues were the first to demonstrate the
importance of myocardial viability to prevent LV dilatation
in a population with successful PCI for the treatmentjection fraction in group 3
SV (ml) EF (%)
line Follow-up P value Baseline Follow-up P value
(22.5) 57.2 (29.3) 0.004 53.5 (11.3) 49.1 (12.3) 0.043
(23.7) 62.5 (21.6) 0.030 52.5 (11.2) 47.6 (9.5) 0.185
(22.3) 55.1 (31.9) 0.034 54.0 (11.4) 49.7 (13.3) 0.115

























































Figure 4 Left ventricular improvement. Percentage of significant
left ventricular (LV) improvement in groups 1 to 3.
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in patients with an open artery was evaluated. Kim and
Braunwald, in the “open artery hypothesis”, proposed that,
in addition to time-dependent myocardial salvage, benefi-
cial effects of reperfusion therapy include attenuation of
LV remodeling and promotion of electrical stability as an
independent effect of an open IRA [25]. Rizzello and
colleagues demonstrated only functional recovery after
revascularization in segments with viable myocardium
(at low-dose dobutamine) in patients with ischemic
cardiomyopathy [26]. Coletta and colleagues showed that
viable myocardium within the infarct zone (contractile re-
serve at low-dose dobutamine at 8 days after anterior
myocardial infarction) obviates LV remodeling [27]. Bel-
lenger and colleagues provided evidence that coronary re-
canalization, even late after AMI (between 3 days and
6 weeks; mean 26 days), can lead to attenuation of subse-
quent LV remodeling. A subset of patients (n = 26) from
the open artery trial (TOAT) was studied. Dobutamine-
stress CMR was used to assess myocardial viability in pa-
tients with anterior myocardial infarction, LV dysfunction,
and isolated proximal occlusion of the left anterior de-
scending coronary artery (LAD), who either underwent
late PCI with a stent to the LAD, or medical treatment
alone. The study demonstrated a significant relation be-
tween the number of viable segments within the infarct
zone and improvement in end-systolic volume index and
EF after revascularization [28]. Furthermore, a nuclear sub-
study of the occluded artery trial (NUC-OAT) investigatedthe influence of infarct-zone viability on ventricular re-
modeling after PCI or optimal medical treatment alone in
a subsequent group of 124 patients [29]. The data from
this study showed that there was no influence of infarct-
zone viability on ventricular remodeling after PCI com-
pared to medical therapy alone in patients with a total
occlusion of the IRA.
Although there are some conflicting data upon this
topic, most data support the theory that full patency of
the IRA and viability are important for reducing both in-
farct expansion in the early phase of infarction and LV
enlargement later on.
In our study, revascularization and the number of vi-
able segments demonstrated by LDDE were both strong
predictors for LVEF improvement at follow-up. The pres-
ence of viability alone was not enough to improve LV
function. Probably, without revascularization a signifi-
cant amount of myocardial viability disappears lacking
optimal recanalization during the follow-up period, as
already demonstrated by Knudsen and colleagues [11].
Furthermore, maximal yield of revascularization in pa-
tients with viability to improve LVEF was seen in patients
with lower EF at baseline. These patients had more viable
segments with the ability to regain function over time
with improvement of LV function. However, even in
patients with preserved LV function after AMI and only
two viable segments (stunned myocardium), revasculariza-
tion remained an independent predictor for further LVEF
improvement.
Study limitations
Because this is a large retrospectively studied population,
multiple biases could have been of influence. In the
VIAMI-trial, patients were randomized to medical treat-
ment or an invasive strategy of coronary revascularization.
Some of the patients in both groups were not treated as
the protocol prescribed. For the purpose of this echocar-
diographic substudy, we divided the patients into three
new groups based on viability and revascularization status.
Therefore, selection bias cannot be excluded; however, no
differences in clinical baseline characteristics were found,
making the three groups well comparable.
No standard angiography was performed in the medic-
ally treated patient group. As a consequence, no infor-
mation about the severity of stenosis or patency of the
IRA is available in this patient group. Therefore, the in-
fluence of viability on LV remodeling in relation to IRA
patency or severity of stenosis was not investigated.
Another point of attention is the use of LDDE for the
detection of viability. Although LDDE is a well validated
and feasible bedside technique, it is prone to inter- and
intra-observer variability. In our study all images were
sent to a core-lab and scored by experienced cardiologists
with low inter-observer variability. Furthermore, sufficient
Table 4 Baseline characteristics and echocardiographic data of patients with or without a significant improvement in
LVEF (>10%) at follow-up
Characteristic No improvement (n = 148) Improvement (n = 76) P value*
Male 80% 70% 0.09
Age (years) 61 61 0.75
Clinical history
Angina 44% 49% 0.50
Myocardial infarction 7% 7% 0.96
Percutaneous coronary intervention 5% 5% 0.86
Coronary artery bypass graft 0% 0% -
In-hospital and follow-up
Anterior infarction 38% 39% 0.81
Thrombolysis 51% 51% 0.93
Peak creatine kinase (U/L) 1802 ± 1439 1567 ± 1245 0.22
Peak creatine kinase-MB (U/L) 185 ± 150 166 ± 159 0.39
Pathological Q waves (n)† 2.1 ± 1.76 1.9 ± 1.58 0.53
Persistent ST elevation > 1 mm† 34% 32% 0.67
Revascularization before follow-up 43% 62% 0.008
Echocardiography
Viable segments (16 segments model) (n) 2.3 ± 1.71 3.2 ± 1.78 <0.001
LVEDV (ml) 89.34 ± 32.44 99.84 ± 27.78 0.012
LVESV (ml) 38.91 ± 21.12 54.84 ± 22.03 <0.001
LV EF (%) 57.66 ± 10.93 45.87 ± 10.31 <0.001
WMI 1.51 ± 0.25 1.62 ± 0.31 0.01
follow-up echocardiogram (days) 208 ± 133 201 ± 127 0.70
Risk factors
Diabetes mellitus 9% 12% 0.50
Hypertension 29% 24% 0.35
Hypercholesterolemia 16% 17% 0.83
Current cigarette smoking 46% 47% 0.91
Family history of coronary artery disease 26% 29% 0.61
Medications at admission
Aspirin 12% 13% 0.74
Beta-blocker 13% 13% 0.96
Statins 10% 12% 0.60
ACE-inhibitor 11% 7% 0.27
Angiotensin II antagonist 7% 3% 0.09
Medications at discharge
Aspirin 94% 95% 0.80
Beta-blocker 95% 93% 0.73
Statins 95% 95% 0.96
ACE-inhibitor 57% 63% 0.36
Angiotensin II antagonist 6% 5% 0.80
Clopidogrel 32% 45% 0.08
Diuretics 8% 9% 0.79
*Differences between the groups. †On the electrocardiogram at 48 hours after acute myocardial infarction. Values are shown as means ± SD unless otherwise
indicated. ACE, angiotensin converting enzyme; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic
volume; WMI, wall motion score index.
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Table 5 Logistic regression analysis: predictors at
baseline of left ventricular ejection fraction improvement
Univariate Multivariate
Variable Wald χ2 P value Wald χ2 P value
Revascularization
before follow-up
6.84 0.009 5.74 0.017
Number of viable
segments
12.84 >0.001 10.31 0.001
LVEDV 5.43 0.02 - -
LVESV 19.57 >0.001 - -
WMI 7.22 0.007 6.22 0.013
LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction;
LVESV, left ventricular end-systolic volume; WMI, wall motion score index.
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80% of a normal study population. This can be improved to
90 to 95% with the use of ultrasound contrast agents [30].
The quality of the images is operator-dependent. In our
study images were recruited from 11 Dutch centers with
many echocardiography technicians. This is one of the rea-
sons for having only 224 patients (out of 291) with suffi-
ciently evaluable echocardiographic images at baseline and
follow-up.
Since this study was conducted between 2001 and 2006,
part of the medical treatment does not apply to today’s
standard. During the inclusion period of the VIAMI-trial,
treatment with clopidogrel was not standard care in pa-
tients without stents. Standard treatment with clopidogrel
according to current guidelines (CLARITY-TIMI 28 trial)
could have made the differences less pronounced [31].
Also the use of angiotensin converting enzyme (ACE) in-
hibitors and angiotensin II antagonists is low at discharge.
During the early days of our study ACE inhibitors were
only given to patients with anterior infarction or LV
systolic dysfunction. Our study population has predomin-
antly a preserved LV function which is in part the explan-
ation for the low use of ACE inhibitors. However, there is
no significant difference in ACE inhibitor use between the
three groups making the influence of ACE inhibition on
the process of remodeling comparable.
Conclusions
We studied patients with AMI who were not treated with
primary or rescue PCI. Revascularization in the patients
with viability in the early phase after AMI leads to a sig-
nificant improvement in LV function whereas, without re-
vascularization, LV volumes increase without change in
EF. The absence of viability results in ventricular dilatation
and deterioration of the LVEF (irrespective of revasculari-
zation status). The number of viable segments and revas-
cularization during the follow-up period (mean 205 days)
are independent predictors for LVEF improvement, espe-
cially in patients with lower EF at baseline.These findings support the importance of a widely patent
IRA in the presence of myocardial viability to improve
LVEF and to prevent LV remodeling. Revascularization in
patients without viability plays no role in the prevention of
remodeling.
Furthermore, the results suggest that patients with a
significant amount of viability should be revascularized
irrespective of the presence or absence of anginal com-
plaints or objective signs of ischemia.
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